The human gut microbiota consists of bacteria, archaea, fungi, and viruses. It is a dynamic ecosystem shaped by several factors that play an essential role in both healthy and diseased states of humans. A disturbance of the gut microbiota, also termed "dysbiosis", is associated with increased host susceptibility to a range of diseases. Because of splanchnic ischemia, exposure to antibiotics, and/or the underlying disease, critically ill patients loose 90% of the commensal organisms in their gut within hours after the insult. This is followed by a rapid overgrowth of potentially pathogenic and pro-inflammatory bacteria that alter metabolic, immune, and even neurocognitive functions and that turn the gut into the driver of systemic inflammation and multiorgan failure. Indeed, restoring healthy microbiota by means of fecal microbiota transplantation (FMT) in the critically ill is an attractive and plausible concept in intensive care. Nonetheless, available data from controlled studies are limited to probiotics and FMT for severe C. difficile infection or severe inflammatory bowel disease. Case series and observational trials have generated hypotheses that FMT might be feasible and safe in immunocompromised patients, refractory sepsis, or severe antibiotic-associated diarrhea in ICU. There is a burning need to test these hypotheses in randomized controlled trials powered for the determination of patient-centered outcomes.

3rd Faculty of Medicine Charles University 11000 Prague Czech Republic

Department of Anesthesiology and Intensive Care Medicine FNKV University Hospital 10034 Prague Czech Republic

Department of Medicine FNKV University Hospital 10034 Prague Czech Republic

Zobrazit více v PubMed

Lamarche D., Johnstone J., Zytaruk N., Clarke F., Hand L., Loukov D., Szamosi J.C., Rossi L., Schenck L.P., Verschoor C.P., et al. Microbial Dysbiosis and Mortality during Mechanical Ventilation: A Prospective Observational Study. Respir. Res. 2018;19:245. doi: 10.1186/s12931-018-0950-5. PubMed DOI PMC

Khanna S. Microbiota Replacement Therapies: Innovation in Gastrointestinal Care. Clin. Pharmacol. Ther. 2018;103:102–111. doi: 10.1002/cpt.923. PubMed DOI

Carvalho B.M., Abdalla Saad M.J. Influence of Gut Microbiota on Subclinical Inflammation and Insulin Resistance. Mediat. Inflamm. 2013;2013:986734. doi: 10.1155/2013/986734. PubMed DOI PMC

Wen L., Duffy A. Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes. J. Nutr. 2017;147:1468S–1475S. doi: 10.3945/jn.116.240754. PubMed DOI PMC

Rastelli M., Knauf C., Cani P.D. Gut Microbes and Health: A Focus on the Mechanisms Linking Microbes, Obesity, and Related Disorders. Obesity. 2018;26:792–800. doi: 10.1002/oby.22175. PubMed DOI PMC

McLean M.H., Dieguez D., Miller L.M., Young H.A. Does the Microbiota Play a Role in the Pathogenesis of Autoimmune Diseases? Gut. 2015;64:332–341. doi: 10.1136/gutjnl-2014-308514. PubMed DOI PMC

Kverka M., Tlaskalova-Hogenova H. Two Faces of Microbiota in Inflammatory and Autoimmune Diseases: Triggers and Drugs. APMIS J. Pathol. Microbiol. Immunol. 2013;121:403–421. doi: 10.1111/apm.12007. PubMed DOI

McClave S.A., Patel J., Bhutiani N. Should Fecal Microbial Transplantation Be Used in the ICU? Curr. Opin. Crit. Care. 2018;24:105–111. doi: 10.1097/MCC.0000000000000489. PubMed DOI

McClave S.A., Lowen C.C., Martindale R.G. The 2016 ESPEN Arvid Wretlind Lecture: The Gut in Stress. Clin. Nutr. 2018;37:19–36. doi: 10.1016/j.clnu.2017.07.015. PubMed DOI

Nakov R., Segal J.P., Settanni C.R.S., Bibb S., Barrini A.G., Cammarota G., Ianiro G. Microbiome: What Intensivists Should Know. Minerva Anestesiol. 2020;86:777–785. doi: 10.23736/S0375-9393.20.14278-0. PubMed DOI

Zaborin A., Smith D., Garfield K., Quensen J., Shakhsheer B., Kade M., Tirrell M., Tiedje J., Gilbert J.A., Zaborina O., et al. Membership and Behavior of Ultra-Low-Diversity Pathogen Communities Present in the Gut of Humans during Prolonged Critical Illness. mBio. 2014;5:e01361-14. doi: 10.1128/mBio.01361-14. PubMed DOI PMC

Wischmeyer P.E., McDonald D., Knight R. Role of the Microbiome, Probiotics, and “dysbiosis Therapy” in Critical Illness. Curr. Opin. Crit. Care. 2016;22:347–353. doi: 10.1097/MCC.0000000000000321. PubMed DOI PMC

Vincent J.-L., Rello J., Marshall J., Silva E., Anzueto A., Martin C.D., Moreno R., Lipman J., Gomersall C., Sakr Y., et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA. 2009;302:2323–2329. doi: 10.1001/jama.2009.1754. PubMed DOI

Wiström J., Norrby S.R., Myhre E.B., Eriksson S., Granström G., Lagergren L., Englund G., Nord C.E., Svenungsson B. Frequency of Antibiotic-Associated Diarrhoea in 2462 Antibiotic-Treated hospitalized Patients: A Prospective Study. J. Antimicrob. Chemother. 2001;50:43–50. doi: 10.1093/jac/47.1.43. PubMed DOI

Prescott H.C., Dickson R.P., Rogers M.A.M., Langa K.M., Iwashyna T.J. Hospitalization Type and Subsequent Severe Sepsis. Am. J. Respir. Crit. Care Med. 2015;192:581–588. doi: 10.1164/rccm.201503-0483OC. PubMed DOI PMC

Schuijt T.J., van der Poll T., de Vos W.M., Wiersinga W.J. The Intestinal Microbiota and Host Immune Interactions in the Critically Ill. Trends Microbiol. 2013;21:221–229. doi: 10.1016/j.tim.2013.02.001. PubMed DOI

Li S., Lv J., Li J., Zhao Z., Guo H., Zhang Y., Cheng S., Sun J., Pan H., Fan S., et al. Intestinal Microbiota Impact Sepsis Associated Encephalopathy via the Vagus Nerve. Neurosci. Lett. 2018;662:98–104. doi: 10.1016/j.neulet.2017.10.008. PubMed DOI

Scott Fridkin M. Morbidity and Mortality Weekly Report. CDC. 2016;9:235–241. PubMed

Batra P., Soni K.D., Mathur P. Efficacy of Probiotics in the Prevention of VAP in Critically Ill ICU Patients: An Updated Systematic Review and Meta-Analysis of Randomized Control Trials. J. Intensive Care. 2020;8:1–14. PubMed PMC

Manzanares W., Lemieux M., Langlois P.L., Wischmeyer P.E. Probiotic and Symbiotic Therapy in Critical Illness: A Systematic Review and Meta-Analysis. Crit. Care. 2016;20:262. doi: 10.1186/s13054-016-1434-y. PubMed DOI PMC

Muñoz P., Bouza E., Cuenca-Estrella M., María E.J., Jesús P.M., Sánchez-Somolinos M., Rincón C., Hortal J., Peláez T. Saccharomyces Cerevisiae Fungemia: An Emerging Infectious Disease. Clin. Infect. Dis. 2005;40:1625–1634. doi: 10.1086/429916. PubMed DOI

Bongaerts G.P.A., Severijnen R.S.V.M. A Reassessment of the PROPATRIA Study and Its Implications for Probiotic Therapy. Nat. Biotechnol. 2016;34:55–63. doi: 10.1038/nbt.3436. PubMed DOI

Allegretti J.R., Mullish B.H., Kelly C., Fischer M. Therapeutics the Evolution of the Use of Faecal Microbiota Transplantation and Emerging Therapeutic Indications. Lancet. 2019;394:420–431. doi: 10.1016/S0140-6736(19)31266-8. PubMed DOI

Ott S.J., Waetzig G.H., Rehman A., Moltzau-Anderson J., Bharti R., Grasis J.A., Cassidy L., Tholey A., Fickenscher H., Seegert D., et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients with Clostridium difficile Infection. Gastroenterology. 2017;152:799–811.e7. doi: 10.1053/j.gastro.2016.11.010. PubMed DOI

McDonald L.C., Gerding D.N., Johnson S., Bakken J.S., Carroll K.C., Coffin S.E., Dubberke E.R., Garey K.W., Gould C.V., Kelly C., et al. Clinical Practice Guidelines for Clostridium Difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) Clin. Infect. Dis. 2018;66:e1–e48. doi: 10.1093/cid/cix1085. PubMed DOI PMC

Quraishi M.N., Widlak M., Bhala N., Moore D., Price M., Sharma N., Iqbal T.H. Systematic Review with Meta-Analysis: The Efficacy of Faecal Microbiota Transplantation for the Treatment of Recurrent and Refractory Clostridium difficile Infection. Aliment. Pharmacol. Ther. 2017;46:479–493. doi: 10.1111/apt.14201. PubMed DOI

Cammarota G., Ianiro G., Kelly C.R., Mullish B.H., Allegretti J.R., Kassam Z., Putignani L., Fischer M., Keller J.J., Costello S.P., et al. International Consensus Conference on Stool Banking for Faecal Microbiota Transplantation in Clinical Practice. Gut. 2019;68:2111–2121. doi: 10.1136/gutjnl-2019-319548. PubMed DOI PMC

Wurm P., Spindelboeck W., Krause R., Plank J., Fuchs G., Bashir M., Petritsch W., Halwachs B., Langner C., Högenauer C., et al. Antibiotic-Associated Apoptotic Enterocolitis in the Absence of a Defined Pathogen: The Role of Intestinal Microbiota Depletion. Crit. Care Med. 2017;45:e600–e606. doi: 10.1097/CCM.0000000000002310. PubMed DOI PMC

Kelly C.R., Ihunnah C., Fischer M., Khoruts A., Surawicz C., Afzali A., Aroniadis O., Barto A., Borody T., Giovanelli A., et al. Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients. Am. J. Gastroenterol. 2014;109:1065–1071. doi: 10.1038/ajg.2014.133. PubMed DOI PMC

Levy A.N., Allegretti J.R. Insights into the Role of Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. Ther. Adv. Gastroenterol. 2019;12:1756284819836893. doi: 10.1177/1756284819836893. PubMed DOI PMC

Antonelli M., Martin-Loeches I., Dimopoulos G., Gasbarrini A., Vallecoccia M.S. Clostridioides difficile (Formerly Clostridium difficile) Infection in the Critically Ill: An Expert Statement. Intensive Care Med. 2020;46:215–224. doi: 10.1007/s00134-019-05873-x. PubMed DOI

Zhang D., Prabhu V.S., Marcella S.W. Attributable Healthcare Resource Utilization and Costs for Patients with Primary and Recurrent Clostridium difficile Infection in the United States. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2018;66:1326–1332. doi: 10.1093/cid/cix1021. PubMed DOI PMC

Cheng Y.-W., Xu H., Phelps E., Rogers N., Sagi S., Bohm M., Kassam Z., Allegretti J., Fishcer M. Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe and Severe Complicated Clostridium difficile Infection Not Eligible for Colectomy. Am. J. Gastroenterol. 2017;112:100

Zilberberg M.D., Nathanson B.H., Sadigov S., Higgins T.L., Kollef M.H., Shorr A.F. Epidemiology and Outcomes of Clostridium difficile-Associated Disease among Patients on Prolonged Acute Mechanical Ventilation. Chest. 2009;136:752–758. doi: 10.1378/chest.09-0596. PubMed DOI

Ro Y., Eun C.S., Kim H.S., Kim J.Y., Byun Y.J., Yoo K.S., Han D.S. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients. Gut Liver. 2016;10:581–586. doi: 10.5009/gnl15324. PubMed DOI PMC

Maseda D., Zackular J.P., Trindade B., Kirk L., Roxas J.L., Rogers L.M., Washington M.K., Du L., Koyama T., Viswanathan V.K., et al. Nonsteroidal Anti-Inflammatory Drugs Alter the Microbiota and Exacerbate Clostridium difficile Colitis while Dysregulating the Inflammatory Response. mBio. 2019;10:e02282-18. doi: 10.1128/mBio.02282-18. PubMed DOI PMC

Marra A.R., Edmond M.B., Wenzel R.P., Bearman G.M.L. Hospital-Acquired Clostridium difficile-associated Disease in the Intensive Care Unit Setting: Epidemiology, Clinical Course and Outcome. BMC Infect. Dis. 2007;7:42. doi: 10.1186/1471-2334-7-42. PubMed DOI PMC

Schneider K.M., Wirtz T.H., Kroy D., Albers S., Neumann U.P., Strowig T., Sellge G., Trautwein C. Successful Fecal Microbiota Transplantation in a Patient with Severe Complicated Clostridium difficile Infection after Liver Transplantation. Case Rep. Gastroenterol. 2018;12:76–84. doi: 10.1159/000481937. PubMed DOI PMC

Al Momani L.A., Abughanimeh O., Boonpherg B., Gabriel J.G., Young M. Fidaxomicin vs. Vancomycin for the Treatment of a First Episode of Clostridium difficile Infection: A Meta-Analysis and Systematic Review. Cureus. 2018;10:e2778. doi: 10.7759/cureus.2778. PubMed DOI PMC

Penziner S., Dubrovskaya Y., Press R., Safdar A. Fidaxomicin Therapy in Critically Ill Patients with Clostridium difficile Infection. Antimicrob. Agents Chemother. 2015;59:1776–1781. doi: 10.1128/AAC.04268-14. PubMed DOI PMC

Sayedy L. Toxic Megacolon Associated Clostridium difficile Colitis. World J. Gastrointest. Endosc. 2010;2:293. doi: 10.4253/wjge.v2.i8.293. PubMed DOI PMC

Cheng Y.W., Phelps E., Nemes S., Rogers N., Sagi S., Bohm M., El-Halabi M., Allegretti J.R., Kassam Z., Xu H., et al. Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection. Clin. Gastroenterol. Hepatol. 2020;18:2234–2243.e1. doi: 10.1016/j.cgh.2019.12.029. PubMed DOI

Ianiro G., Masucci L., Quaranta G., Simonelli C., Lopetuso L.R., Sanguinetti M., Gasbarrini A., Cammarota G. Randomised Clinical Trial: Faecal Microbiota Transplantation by Colonoscopy plus Vancomycin for the Treatment of Severe Refractory Clostridium difficile Infection—Single versus Multiple Infusions. Aliment. Pharmacol. Ther. 2018;48:152–159. doi: 10.1111/apt.14816. PubMed DOI

Hocquart M., Lagier J.C., Cassir N., Saidani N., Eldin C., Kerbaj J., Delord M., Valles C., Brouqui P., Raoult D., et al. Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections. Clin. Infect. Dis. 2018;66:645–650. doi: 10.1093/cid/cix762. PubMed DOI

Fischer M., Sipe B., Cheng Y.W., Phelps E., Rogers N., Sagi S., Bohm M., Xu H., Kassam Z. Fecal Microbiota Transplant in Severe and Severe-Complicated Clostridium difficile: A Promising Treatment Approach. Gut Microbes. 2017;8:289–302. doi: 10.1080/19490976.2016.1273998. PubMed DOI PMC

Zainah H., Hassan M., Shiekh-Sroujieh L., Hassan S., Alangaden G., Ramesh M. Intestinal Microbiota Transplantation, a Simple and Effective Treatment for Severe and Refractory Clostridium difficile Infection. Dig. Dis. Sci. 2015;60:181–185. doi: 10.1007/s10620-014-3296-y. PubMed DOI

Luo Y., Tixier E.N., Grinspan A.M. Fecal Microbiota Transplantation for Clostridioides difficile in High-Risk Older Adults Is Associated with Early Recurrence. Dig. Dis. Sci. 2020;65:3647–3651. doi: 10.1007/s10620-020-06147-z. PubMed DOI

Aroniadis O.C., Brandt L.J., Greenberg A., Borody T., Kelly C.R., Mellow M., Surawicz C., Cagle L., Neshatian L., Stollman N., et al. Long-Term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience. J. Clin. Gastroenterol. 2016;50:398–402. doi: 10.1097/MCG.0000000000000374. PubMed DOI

Alukal J., Dutta S.K., Surapaneni B.K., Le M., Tabbaa O., Phillips L., Mattar M.C. Safety and Efficacy of Fecal Microbiota Transplant in 9 Critically Ill Patients with Severe and Complicated Clostridium difficile Infection with Impending Colectomy. J. Dig. Dis. 2019;20:301–307. doi: 10.1111/1751-2980.12750. PubMed DOI

Fischer M., Kao D., Mehta S.R., Martin T., Dimitry J., Keshteli A.H., Cook G.K., Phelps E., Sipe B.W., Xu H., et al. Predictors of Early Failure after Fecal Microbiota Transplantation for the Therapy of Clostridium difficile Infection: A Multicenter Study. Am. J. Gastroenterol. 2016;111:1024–1031. doi: 10.1038/ajg.2016.180. PubMed DOI

Ianiro G., Valerio L., Masucci L., Pecere S., Bibbò S., Quaranta G., Posteraro B., Currò D., Sanguinetti M., Gasbarrini A., et al. Predictors of Failure after Single Faecal Microbiota Transplantation in Patients with Recurrent Clostridium difficile Infection: Results from a 3-Year, Single-Centre Cohort Study. Clin. Microbiol. Infect. 2017;23:337.e1–337.e3. doi: 10.1016/j.cmi.2016.12.025. PubMed DOI

Cheng Y.W., Phelps E., Ganapini V., Khan N., Ouyang F., Xu H., Khanna S., Tariq R., Friedman-Moraco R.J., Woodworth M.H., et al. Fecal Microbiota Transplantation for the Treatment of Recurrent and Severe Clostridium difficile Infection in Solid Organ Transplant Recipients: A Multicenter Experience. Am. J. Transplant. 2019;19:501–511. doi: 10.1111/ajt.15058. PubMed DOI PMC

Agrawal M., Aroniadis O.C., Brandt L.J., Kelly C., Freeman S., Surawicz C., Broussard E., Stollman N., Giovanelli A., Smith B., et al. The Long-Term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. J. Clin. Gastroenterol. 2016;50:403–407. doi: 10.1097/MCG.0000000000000410. PubMed DOI

Fischer M., Sipe B.W., Rogers N.A., Cook G.K., Robb B.W., Vuppalanchi R., Rex D.K. Faecal Microbiota Transplantation plus Selected Use of Vancomycin for Severe-Complicated Clostridium difficile Infection: Description of a Protocol with High Success Rate. Aliment. Pharmacol. Ther. 2015;42:470–476. doi: 10.1111/apt.13290. PubMed DOI

Giovanni C. Decrease in Surgery for Clostridium difficile Infection After Starting a Program to Transplant Fecal Microbiota. Ann. Intern. Med. 2015;162:533–541. PubMed

Weingarden A.R., Hamilton M.J., Sadowsky M.J., Khoruts A. Resolution of Severe Clostridium difficile Infection Following Sequential Fecal Microbiota Transplantation. J. Clin. Gastroenterol. 2013;47:735–737. doi: 10.1097/MCG.0b013e31829004ae. PubMed DOI PMC

Berro Z.Z., Hamdan R.H., Dandache I.H., Saab M.N., Karnib H.H., Younes M.H. Fecal Microbiota Transplantation for Severe Clostridium difficile Infection after Left Ventricular Assist Device Implantation: A Case Control Study and Concise Review on the Local and Regional Therapies. BMC Infect. Dis. 2016;16:234. doi: 10.1186/s12879-016-1571-6. PubMed DOI PMC

You D.M., Franzos M.A., Holman R.P. Successful Treatment of Fulminant Clostridium difficile Infection with Fecal Bacteriotherapy. Ann. Intern. Med. 2008;148:632–633. doi: 10.7326/0003-4819-148-8-200804150-00024. PubMed DOI

Yu S., Abdelkarim A., Nawras A., Hinch B.T., Mbaso C., Valavoor S., Safi F., Hammersley J., Tang J., Assaly R. Fecal Transplant. for Treatment of Toxic Megacolon Associated with Clostridium difficile Colitis in a Patient with Duchenne Muscular Dystrophy. Am. J. Ther. 2016;23:e609–e613. doi: 10.1097/MJT.0000000000000062. PubMed DOI

Trubiano J.A., Gardiner B., Kwong J.C., Ward P., Testro A.G., Charles P.G.P. Faecal Microbiota Transplantation for Severe Clostridium difficile Infection in the Intensive Care Unit. Eur. J. Gastroenterol. Hepatol. 2013;25:255–257. doi: 10.1097/MEG.0b013e32835b2da9. PubMed DOI

Brechmann T., Swol J., Knop-Hammad V., Willert J., Aach M., Cruciger O., Schmiegel W., Schildhauer T.A., Hamsen U. Complicated Fecal Microbiota Transplantation in a Tetraplegic Patient with Severe Clostridium difficile Infection. World J. Gastroenterol. 2015;21:3736–3740. doi: 10.3748/wjg.v21.i12.3736. PubMed DOI PMC

Lee M.S.L., Ramakrishna B., Moss A.C., Gold H.S., Branch-Elliman W. Successful Treatment of Fulminant Clostridioides difficile Infection with Emergent Fecal Microbiota Transplantation in a Patient with Acute Myeloid Leukemia and Prolonged, Severe Neutropenia. Transplant. Infect. Dis. 2020;22:e13216. doi: 10.1111/tid.13216. PubMed DOI

Martínez-Ayala P., González-Hernández L.A., Amador-Lara F., Andrade-Villanueva J., Ramos-Solano M. Trasplante de Microbiota Fecal En El Tratamiento de Colitis Grave Complicada Por, C. difficile En Un Paciente Con Síndrome de Inmunodeficiencia Adquirida. Rev. Gastroenterol. Méx. 2019;84:110–112. doi: 10.1016/j.rgmx.2017.12.002. PubMed DOI

Neemann K., Eichele D.D.D., Smith P.P.W., Bociek R., Akhtari M., Freifeld A. Fecal Microbiota Transplantation for Fulminant Clostridium difficile Infection in an Allogeneic Stem Cell Transplant Patient. Transplant. Infect. Dis. 2012;14:E161–E165. doi: 10.1111/tid.12017. PubMed DOI

Krajicek E., Bohm M., Sagi S., Fischer M. Fulminant Clostridium difficile Infection Cured by Fecal Microbiota Transplantation in a Bone Marrow Transplant Recipient with Critical Neutropenia. ACG Case Rep. J. 2019;6:e00198. doi: 10.14309/crj.0000000000000198. PubMed DOI PMC

Gallegos-Orozco J.F., Paskvan-Gawryletz C.D., Gurudu S.R., Orenstein R. Successful Colonoscopic Fecal Transplant for Severe Acute Clostridium difficile Pseudomembranous Colitis. Rev. Gastroenterol. Mex. 2012;77:40–42. PubMed

Zuo T., Ng S.C. The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. Front. Microbiol. 2018;9:2247. doi: 10.3389/fmicb.2018.02247. PubMed DOI PMC

Oka A., Sartor R.B. Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases. Dig. Dis. Sci. 2020;65:757–788. doi: 10.1007/s10620-020-06090-z. PubMed DOI PMC

Lucio C.M.K. Clostridium difficile Infection and Chronic Inflammatory Bowel Disease. World J. Gastroenterol. 2013;9:7577–7585. PubMed PMC

Khoruts A., Rank K.M., Newman K.M., Viskocil K., Vaughn B.P., Hamilton M.J., Sadowsky M.J. Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Clin. Gastroenterol. Hepatol. 2016;14:1433–1438. doi: 10.1016/j.cgh.2016.02.018. PubMed DOI PMC

Cui B., Feng Q., Wang H., Wang M., Peng Z., Li P., Huang G., Liu Z., Wu P., Fan Z., et al. Fecal Microbiota Transplantation through Mid-Gut for Refractory Crohn’s Disease: Safety, Feasibility, and Efficacy Trial Results. J. Gastroenterol. Hepatol. 2015;30:51–58. doi: 10.1111/jgh.12727. PubMed DOI

Tan P., Li X., Shen J., Feng Q. Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update. Front. Pharmacol. 2020;11:1409. doi: 10.3389/fphar.2020.574533. PubMed DOI PMC

Moayyedi P., Surette M.G., Kim P.T., Libertucci J., Wolfe M., Onischi C., Armstrong D., Marshall J.K., Kassam Z., Reinisch W., et al. Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015;149:102–109.e6. doi: 10.1053/j.gastro.2015.04.001. PubMed DOI

Paramsothy S., Paramsothy R., Rubin D.T., Kamm M.A., Kaakoush N.O., Mitchell H.M., Castaño-Rodríguez N. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J. Crohn’s Colitis. 2017;11:1180–1199. doi: 10.1093/ecco-jcc/jjx063. PubMed DOI

Basso P.J., Saraiva Câmara N.O., Sales-Campos H. Microbial-Based Therapies in the Treatment of Inflammatory Bowel Disease—An Overview of Human Studies. Front. Pharmacol. 2019;9:1571. doi: 10.3389/fphar.2018.01571. PubMed DOI PMC

Uygun A., Ozturk K., Demirci H., Oger C., Avci I.Y., Turker T., Gulsen M. Fecal Microbiota Transplantation Is a Rescue Treatment Modality for Refractory Ulcerative Colitis. Medicine. 2017;96:e6479. doi: 10.1097/MD.0000000000006479. PubMed DOI PMC

Ishikawa D., Sasaki T., Osada T., Kuwahara-Arai K., Haga K., Shibuya T., Hiramatsu K., Watanabe S. Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis. Inflamm. Bowel Dis. 2017;23:116–125. doi: 10.1097/MIB.0000000000000975. PubMed DOI

Kump P., Wurm P., Gröchenig H.P., Wenzl H., Petritsch W., Halwachs B., Wagner M., Stadlbauer V., Eherer A., Hoffmann K.M., et al. The Taxonomic Composition of the Donor Intestinal Microbiota Is a Major Factor Influencing the Efficacy of Faecal Microbiota Transplantation in Therapy Refractory Ulcerative Colitis. Aliment. Pharmacol. Ther. 2018;47:67–77. doi: 10.1111/apt.14387. PubMed DOI PMC

Okahara K., Ishikawa D., Nomura K., Ito S., Haga K., Takahashi M., Shibuya T., Osada T., Nagahara A. Matching between Donors and Ulcerative Colitis Patients Is Important for Long-Term Maintenance after Fecal Microbiota Transplantation. J. Clin. Med. 2020;9:1650. doi: 10.3390/jcm9061650. PubMed DOI PMC

Vermeire S., Joossens M., Verbeke K., Wang J., Machiels K., Sabino J., Ferrante M., van Assche G., Rutgeerts P., Raes J. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J. Crohn’s Colitis. 2016;10:387–394. doi: 10.1093/ecco-jcc/jjv203. PubMed DOI PMC

Karakan T., İbiş M., Cindoruk M., Sargin Z.G., Alizadeh N., Colman R., Rubin D. P639 Faecal Microbiota Transplantation as a Rescue Therapy for Steroid-Dependent and/or Non-Responsive Patients with Ulcerative Colitis: A Pilot Study. P640 Co-Detection of Infliximab and Antibodies in an ECLIA Assay amongst IBD Patients Treated with Infliximab. Curr. Drug. Targets. 2020;21:1440–1447. PubMed

Borody T.J., Warren E.F., Leis S., Surace R., Ashman O. Treatment of Ulcerative Colitis Using Fecal Bacteriotherapy. J. Clin. Gastroenterol. 2003;37:42–47. doi: 10.1097/00004836-200307000-00012. PubMed DOI

Chen M., Liu X.L., Zhang Y.J., Nie Y.Z., Wu K.C., Shi Y.Q. Efficacy and Safety of Fecal Microbiota Transplantation by Washed Preparation in Patients with Moderate to Severely Active Ulcerative Colitis. J. Dig. Dis. 2020;21:621–628. doi: 10.1111/1751-2980.12938. PubMed DOI PMC

Dang X.-F., Wang Q.-X., Yin Z., Sun L., Yang W.-H. Recurrence of Moderate to Severe Ulcerative Colitis after Fecal Microbiota Transplantation Treatment and the Efficacy of Re-FMT: A Case Series. BMC Gastroenterol. 2020;20:88. doi: 10.1186/s12876-020-01548-w. PubMed DOI PMC

Fischer M., Kao D., Kelly C., Kuchipudi A., Jafri S.M., Blumenkehl M., Rex D., Mellow M., Kaur N., Sokol H., et al. Fecal Microbiota Transplantation Is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2016;22:2402–2409. doi: 10.1097/MIB.0000000000000908. PubMed DOI

Sood A., Singh A., Mahajan R., Midha V., Kaur K., Singh D., Bansal N., Dharni K. Clinical Predictors of Response to Faecal Microbiota Transplantation in Patients with Active Ulcerative Colitis. J. Crohn’s Colitis. 2021;15:238–243. doi: 10.1093/ecco-jcc/jjaa163. PubMed DOI

Mizuno S., Nanki K., Matsuoka K., Saigusa K., Ono K., Arai M., Sugimoto S., Kiyohara H., Nakashima M., Takeshita K., et al. Single Fecal Microbiota Transplantation Failed to Change Intestinal Microbiota and Had Limited Effectiveness against Ulcerative Colitis in Japanese Patients. Intest. Res. 2017;15:68–74. doi: 10.5217/ir.2017.15.1.68. PubMed DOI PMC

Wang Y., Ren R., Sun G., Peng L., Tian Y., Yang Y. Pilot Study of Cytokine Changes Evaluation after Fecal Microbiota Transplantation in Patients with Ulcerative Colitis. Int. Immunopharmacol. 2020;85:106661. doi: 10.1016/j.intimp.2020.106661. PubMed DOI

Costello S.P., Day A., Yao C.K., Bryant R.V. Faecal Microbiota Transplantation (FMT) with Dietary Therapy for Acute Severe Ulcerative Colitis. BMJ Case Rep. 2020;13:e233135. doi: 10.1136/bcr-2019-233135. PubMed DOI PMC

Li Q., Wang C., Tang C., He Q., Zhao X., Li N., Li J. Successful Treatment of Severe Sepsis and Diarrhea after Vagotomy Utilizing Fecal Microbiota Transplantation: A Case Report. Crit. Care. 2015;19:37. doi: 10.1186/s13054-015-0738-7. PubMed DOI PMC

Wei Y., Yang J., Wang J., Yang Y., Huang J., Gong H., Cui H., Chen D. Successful Treatment with Fecal Microbiota Transplantation in Patients with Multiple Organ Dysfunction Syndrome and Diarrhea Following Severe Sepsis. Crit. Care. 2016;20:332. doi: 10.1186/s13054-016-1491-2. PubMed DOI PMC

Wei Y., Li N., Xing H., Guo T., Gong H., Chen D. Effectiveness of Fecal Microbiota Transplantation for Severe Diarrhea after Drug-Induced Hypersensitivity Syndrome. Medicine. 2019;98:e18476. doi: 10.1097/MD.0000000000018476. PubMed DOI PMC

Dai M., Liu Y., Chen W., Buch H., Shan Y., Chang L., Bai Y., Shen C., Zhang X., Huo Y., et al. Rescue Fecal Microbiota Transplantation for Antibiotic-Associated Diarrhea in Critically Ill Patients. Crit. Care. 2019;23:284. doi: 10.1186/s13054-019-2604-5. PubMed DOI PMC

Li Q., Wang C., Tang C., He Q., Zhao X., Li N., Li J. Therapeutic Modulation and Reestablishment of the Intestinal Microbiota with Fecal Microbiota Transplantation Resolves Sepsis and Diarrhea in a Patient. Am. J. Gastroenterol. 2014;109:1832–1834. doi: 10.1038/ajg.2014.299. PubMed DOI

Gopalsamy S.N., Sherman A., Woodworth M.H., Lutgring J.D., Kraft C.S. Fecal Microbiota Transplant for Multidrug-Resistant Organism Decolonization Administered during Septic Shock. Infect. Control Hosp. Epidemiol. 2018;39:490–492. doi: 10.1017/ice.2017.300. PubMed DOI PMC

Wei Y., Gong J., Zhu W., Guo D., Gu L., Li N., Li J. Fecal Microbiota Transplantation Restores Dysbiosis in Patients with Methicillin Resistant Staphylococcus aureus Enterocolitis. BMC Infect. Dis. 2015;15:265. doi: 10.1186/s12879-015-0973-1. PubMed DOI PMC

Ueckermann V., Hoosien E., de Villiers N., Geldenhuys J. Fecal Microbial Transplantation for the Treatment of Persistent Multidrug-Resistant Klebsiella pneumoniae Infection in a Critically Ill Patient. Case Rep. Infect. Dis. 2020;2020:8462659. doi: 10.1155/2020/8462659. PubMed DOI PMC

Spindelboeck W., Schulz E., Uhl B., Kashofer K., Aigelsreiter A., Zinke-Cerwenka W., Mulabecirovic A., Kump P.K., Halwachs B., Gorkiewicz G., et al. Repeated Fecal Microbiota Transplantations Attenuate Diarrhea and Lead to Sustained Changes in the Fecal Microbiota in Acute, Refractory Gastrointestinal Graft-versus-Host-Disease. Haematologica. 2017;102:e210–e213. doi: 10.3324/haematol.2016.154351. PubMed DOI PMC

Ubeda C., Bucci V., Caballero S., Djukovic A., Toussaint N.C., Equinda M., Lipuma L., Ling L., Gobourne A., No D., et al. Intestinal Microbiota Containing Barnesiella Species Cures Vancomycin-Resistant Enterococcus faecium Colonization. Infect. Immun. 2013;81:965–973. doi: 10.1128/IAI.01197-12. PubMed DOI PMC

Bilinski J., Grzesiowski P., Sorensen N., Madry K., Muszynski J., Robak K., Wroblewska M., Dzieciatkowski T., Dulny G., Dwilewicz-Trojaczek J., et al. Fecal Microbiota Transplantation in Patients with Blood Disorders Inhibits Gut Colonization with Antibiotic-Resistant Bacteria: Results of a Prospective, Single-Center Study. Clin. Infect. Dis. 2017;65:364–370. doi: 10.1093/cid/cix252. PubMed DOI

Huttner B.D., de Lastours V., Wassenberg M., Maharshak N., Mauris A., Galperine T., Zanichelli V., Kapel N., Bellanger A., Olearo F., et al. A 5-Day Course of Oral Antibiotics Followed by Faecal Transplantation to Eradicate Carriage of Multidrug-Resistant Enterobacteriaceae: A Randomized Clinical Trial. Clin. Microbiol. Infect. 2019;25:830–838. doi: 10.1016/j.cmi.2018.12.009. PubMed DOI

Allogenic faecal microbiota transplantation for antibiotic-associated diarrhoea in critically ill patients (FEBATRICE)-Study protocol for a multi-centre randomised controlled trial (phase II)

Evaluating Bacterial Viability in Faecal Microbiota Transplantation: A Comparative Analysis of In Vitro Cultivation and Membrane Integrity Methods